Navigation Links
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
Date:6/17/2008

gress from these clinical programs with the medical community and our investors."

In addition to the PX-866 trial, Oncothyreon is conducting a Phase 2 trial of PX-12, an inhibitor of thioredoxin-1, in advanced pancreatic cancer, a Phase 1b trial of PX-12 in advanced metastatic cancer, and a Phase 1 trial of PX-478, a small molecule inhibitor of hypoxia inducible factor-1 alpha, in patients with advanced solid tumors or lymphomas. Oncothyreon's partner, Merck KGaA of Darmstadt, Germany, is conducting a Phase 3 trial of Stimuvax(R), an investigational therapeutic cancer vaccine, in patients with stage III non-small cell lung cancer.

About PX-866

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Aberrant activation and regulation of PI-3 kinase is implicated in a large proportion of human cancers including breast, glioma, colon, ovarian, prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous administration. The compound has been shown to have anti-tumor activity both as a single agent and in combination with other agents in a number of human tumor models.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
(Date:7/29/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today announced ... Officer has resigned.  The Company has hired Andrew ... in December 2014, as full time interim CFO and ... Andy Ashworth began his employment today, ... transition.  Andy was the Company,s CFO from September 2011 ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global leader ... . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard ... an example of an accurate label, and pictogram uses and meanings. , “With ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2
... June 3 OriGene Technologies, Inc., a leading gene-centric ... of over 5,000 heavy isotope labeled human proteins as internal standards ... The announcement was made at the 2010 American Society for ... , , ...
... 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that ... executive vice president and CFO, will provide an update on the progress of ... at two investor conferences during the month of June: , ... The Jefferies 2010 Global Life ...
... YORK , June 3 Reportlinker.com announces that a new market research report is ... Nanobiotechnologies- applications, markets and companies ... http://www.reportlinker.com/p0203545/Nanobiotechnologies--applications-markets-and-companies.html , , ... , , ...
Cached Biology Technology:OriGene Technologies Launches Over 5,000 Heavy Isotope Labeled Full-Length Human Proteins as Quantitative Internal Standards for SRM/MRM Mass Spectrometry 2Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 2Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 3Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 4Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 5Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 6Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 7Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 8Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 9Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 10Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 11Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 12Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 13Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 14Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 15Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 16Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 17Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 18Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 19Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 20Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 21Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 22Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 23Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 24Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 25Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 26Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 27Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 28Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 29Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 30
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... School of Medicine in St. Louis, living cells gobbled ... of the unusual meal, the cells were easily located ... , Developed in the laboratories of Samuel A. Wickline, ... soon allow researchers and physicians to directly track cells ...
... As climate change continues to make headlines across the ... are hearing how Earth observation satellites allow scientists to ... how this is impacting the planet. , The cryosphere ... on climate. Because any increase in the melt rate ...
... two strategies to reactivate the p53 gene in mice, causing ... protein is called the "guardian of the genome" because it ... of p53 can set the stage for the development of ... first time that inactivating the p53 gene is necessary for ...
Cached Biology News:Nanoparticles can track cells deep within living organisms 2Nanoparticles can track cells deep within living organisms 3Satellites shed light on global warming 2Satellites shed light on global warming 3Satellites shed light on global warming 4Satellites shed light on global warming 5Turning a cellular sentinel into a cancer killer 2Turning a cellular sentinel into a cancer killer 3Turning a cellular sentinel into a cancer killer 4
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
fli-1...
Purified Mouse anti-Hu p120 Catenin (pT916) Storage Temperature: Refrigerate(2 to 8C)...
Request Info...
Biology Products: